ArticleScientific reports2015
Uric acid enhances the antitumor immunity of dendritic cell-based vaccine.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Linking Hyperuricemia to Cancer: Emerging Evidence on Risk and Progression.Current oncology reports · 2025Pooled it
- Systematic Overview of Solid Particles and Their Host Responses.Frontiers in immunology · 2018Pooled it
- A programmable nanoreactor for photothermal immunotherapy via NIR-II triggered enzyme-catalyzed immunogenic tumor microenvironment remodeling.Asian journal of pharmaceutical sciences · 2026Article
- Nutrition and Diet Patterns as Key Modulators of Metabolic Reprogramming in Melanoma Immunotherapy.Journal of clinical medicine · 2025Review
- Artificial metabzyme-driven metabolic reprogramming and precision oncology.Clinical and translational medicine · 2025Article
- Immunogenic cell death-related signature predicts prognosis and immunotherapy efficacy in bladder cancer.Translational cancer research · 2024Article
- An artificial metabzyme for tumour-cell-specific metabolic therapy.Nature nanotechnology · 2024Article
- Uric acid-driven NLRP3 inflammasome activation triggers lens epithelial cell senescence and cataract formation.Cell death discovery · 2024Article
- Association between serum uric acid and colorectal cancer risk in European population: a two-sample Mendelian randomization study.Frontiers in oncology · 2024Article
- Hyperuricemia is accompanied by elevated peripheral CD4Scientific reports · 2023Article
- An Overview on Immunogenic Cell Death in Cancer Biology and Therapy.Pharmaceutics · 2022Review
- The double faced role of xanthine oxidoreductase in cancer.Acta pharmacologica Sinica · 2022Review
- Urate-induced immune programming: Consequences for gouty arthritis and hyperuricemia.Immunological reviews · 2020Review
- Male asymptomatic hyperuricemia patients display a lower number of NKG2D+ NK cells before and after a low-purine diet.Medicine · 2018Article
- A pan-cancer study of the transcriptional regulation of uricogenesis in human tumours: pathological and pharmacological correlates.Bioscience reports · 2018Article
- TNP-470 skews DC differentiation to Th1-stimulatory phenotypes and can serve as a novel adjuvant in a cancer vaccine.Blood advances · 2018Article
- The spectrum of T cell metabolism in health and disease.Nature reviews. Immunology · 2018Review
- Urate crystals directly activate the T-cell receptor complex and induce T-cell proliferation.Biomedical reports · 2017Article
- Dendritic cell vaccines: A review of recent developments and their potential pediatric application.Human vaccines & immunotherapeutics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uric acid (UA) released from dying cells has been recognized by the immune system as a danger signal. In response to UA, dendritic cells (DC) in the immune system mature and enhance the T cell response to foreign antigens. It is conceivable that the antitumor immunity of a tumor vaccine could be promoted by the administration of UA. To test this concept, we applied UA as an adjuvant to a DC-based vaccine, and discovered that the administration of UA as an adjuvant significantly enhanced the ability of the tumor lysate-pulsed DC vaccine in delaying the tumor growth. The antitumor activity was achieved with adoptively transferred lymphocytes, and both CD8(+) T cells and NK cells were required to achieve effective immunity. This resulted in an increased accumulation of activated CD8(+) T cells and an elevated production of IFN-γ. Collectively, our study shows that the administration of UA enhances the antitumor activity of tumor lysate-pulsed DC vaccine, thus providing the preclinical rationale for the application of UA in DC-based vaccine strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.